Skip to main content

Table 4 Effect of age and gender on mean difference in FSIQ

From: The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI

 

Difference in mean FSIQ

(95% CI)

p-value

Difference in mean FSIQ

(95% CI)

p-value

 

Age < 5

Age > 5

 

Male

Female

 

Controls vs. patients

3 years

7.7

(3.7: 11.7)

5.0

(1.2: 8.8)

ns

8.3

(4.5: 12.1)

5.6

(1.7: 9.5)

ns

5 years

5.6

(1.3: 9.9)

3.6

(-1.5: 8.7)

ns

5.5

(1.1: 9.9)

4.6

(-0.4: 9.6)

ns

HDM vs. IT MTX

3 years

-0.1

(-4.9: 4.6)

1.0

(-5.7: 7.7)

ns

-0.9

(-6.4: 4.5)

0.0

(-5.7: 5.8)

ns

5 years

1.6

(-3.5: 6.7)

-6.6

(-14.5: 1.3)

ns

-1.3

(-7.6: 5.0)

-1.7

(-8.0: 4.6)

ns

HDM vs. XRT

3 years

4.2

(-3.4: 11.9)

4.2

(-3.5: 11.8)

ns

3.6

(-3.8: 11.0)

4.8

(-3.1: 12.6)

ns

5 years

5.5

(-5.9: 13.4)

-0.4

(-10.8: 10.0)

ns

2.1

(-7.0: 11.2)

1.5

(-12.2: 15.2)

ns